USA - March 30 2021
According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s…
Aron Fischer, Matthew Weiss
USA - March 8 2021
The fight over proposed Enbrel® (etanercept) biosimilar Erelzi® continues. Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (“Sandoz”) recently…
Matthew Weiss
USA - February 9 2021
On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed…
Matthew Weiss
USA - February 1 2021
The last two years saw the launch of several biosimilars. Looking ahead to 2021, several others may be on the horizon. In 2019-2020, the FDA approved…
Matthew Weiss
USA - January 28 2021
The Federal Circuit has spoken. In a per curiam opinion, it denied Valeant’s petition for rehearing by the panel and rehearing en banc. A case…
Andrew D. Cohen, Matthew Weiss